Published in Proc Natl Acad Sci U S A on July 15, 1993
Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 1.93
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine (1997) 1.32
Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. PLoS One (2009) 0.94
Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med (1996) 0.93
SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine (2010) 0.84
Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 9.73
The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell (1988) 6.28
Viruses in human cancers. Science (1991) 4.58
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol (1991) 4.18
Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res (1989) 3.07
Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J Virol (1986) 3.03
Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J Virol (1989) 3.02
The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J Virol (1992) 2.61
Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet (1990) 2.54
Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J (1989) 1.84
Role of the human papillomaviruses in human cancer. Cancer Res (1991) 1.56
Human papillomavirus detection in paraffin-embedded cervical carcinomas and metastases of the carcinomas by the polymerase chain reaction. Am J Pathol (1989) 1.53
Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A (1991) 1.47
Induction of human cervical squamous cell carcinoma by sequential transfection with human papillomavirus 16 DNA and viral Harvey ras. Oncogene (1989) 1.46
Human papillomaviruses and carcinomas. Adv Virus Res (1989) 1.46
Relation of spontaneous transformation in cell culture to adaptive growth and clonal heterogeneity. Proc Natl Acad Sci U S A (1990) 1.39
Human papillomavirus 16 DNA in cervical cancers and in lymph nodes of cervical cancer patients: a diagnostic marker for early metastases? Int J Cancer (1989) 1.35
Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proc Natl Acad Sci U S A (1988) 1.24
Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol (1992) 1.18
Transcriptional activation of several heterologous promoters by the E6 protein of human papillomavirus type 16. J Virol (1992) 1.14
Ras-responsive genes and tumor metastasis. Crit Rev Oncog (1993) 1.13
Human papillomavirus deoxyribonucleic acid in cervical carcinoma from primary and metastatic sites. Am J Obstet Gynecol (1986) 1.11
Human papillomavirus DNA in distant metastases of cervical cancer. Gynecol Oncol (1993) 1.00
In situ localization of human papilloma virus type 16 DNA in a metastasis of an endocervical adenocarcinoma. Intervirology (1987) 0.98
Prognostic significance of the presence of human papillomavirus DNA in patients with invasive carcinoma of the cervix. Cancer (1989) 0.90
Oncogene-mediated effects on cellular gene expression. Crit Rev Oncog (1993) 0.90
The transformed phenotype in culture and tumorigenicity of Fischer rat fibroblast cells (FR3T3) transformed with bovine papilloma virus type 1. Virology (1984) 0.90
Clonal analysis of variant cell lines transformed to malignant cells in tissue culture. J Natl Cancer Inst (1959) 0.89
Differential early viral gene expression in two stages of human papillomavirus type 16 DNA-induced malignant transformation. Mol Cell Biol (1987) 0.89
Prevalence and distribution of human papillomavirus type-16 DNA in pelvic lymph nodes of patients with cervical cancer and in women with no history of cervical abnormality. Int J Cancer (1992) 0.85
Prognostic importance of human papillomavirus type 16 DNA in cervical cancer. Cancer (1992) 0.80
Human papillomavirus DNA as a possible index of invasiveness in female genital tract carcinomas. Eur J Cancer (1991) 0.79
The use of in situ hybridization to show human papillomavirus deoxyribonucleic acid in metastatic cancer cells within lymph nodes. Am J Obstet Gynecol (1990) 0.79
Differences in the integration pattern and episomal forms of human papillomavirus type 16 DNA found within an invasive cervical neoplasm and its metastasis. Virology (1992) 0.79
Anogenital papillomavirus infection and neoplasia in immunodeficient women: an update. Dermatol Clin (1991) 0.78
Analysis of fine-needle aspirates for HPV by PCR may be useful in diagnosis of metastatic gynecologic malignancies. Gynecol Oncol (1992) 0.77
Immune response to papillomavirus infections. Curr Probl Dermatol (1989) 0.77
Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (1998) 7.81
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med (1992) 5.96
Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A (1971) 5.38
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med (1996) 4.51
Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst (1998) 4.42
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell (1992) 4.34
Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol (1996) 4.25
The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol (1991) 4.18
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Cellular immunity against tumor antigens. Adv Cancer Res (1969) 3.70
Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol (1993) 3.65
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Epidemiology of genital human papillomavirus infection. Epidemiol Rev (1988) 3.32
Abrogation of cellular immunity to antigenically foreign mouse embryonic cells by a serum factor. Nature (1969) 3.20
Immunological enhancement as studied by cell culture techniques. Annu Rev Microbiol (1970) 3.12
Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer (1971) 3.06
Neutralizing monoclonal antibodies to the AIDS virus. AIDS (1988) 3.06
Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer (1971) 2.88
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A (1999) 2.87
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature (1987) 2.82
Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas. Int J Cancer (1969) 2.80
Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol (1974) 2.68
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev (1997) 2.65
Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol (1998) 2.64
The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J Virol (1992) 2.61
Cellular and humoral immunity to different types of human neoplasms. Nature (1968) 2.40
Cell surface antigens of human melanoma identified by monoclonal antibody. Proc Natl Acad Sci U S A (1979) 2.40
Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci U S A (1969) 2.28
The oncogenic potential of herpes simplex viruses: evidence for a 'hit-and-run' mechanism. Nature (1983) 2.26
Phosphorylation of synthetic peptides by a tyrosine protein kinase from the particulate fraction of a lymphoma cell line. Proc Natl Acad Sci U S A (1982) 2.25
Detection of herpes simplex RNA in human sensory ganglia. Virology (1979) 2.23
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol (2001) 2.18
Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc Natl Acad Sci U S A (1980) 2.14
Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Natl Acad Sci U S A (1968) 2.12
Limited transcription of the herpes simplex virus genome when latent in human sensory ganglia. J Virol (1982) 2.12
Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst (1997) 2.06
Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci U S A (1994) 2.02
The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol (1994) 1.97
Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 1.93
Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res (1996) 1.93
Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res (2001) 1.89
Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169. J Virol (1982) 1.88
Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol (1998) 1.84
Genital human papillomavirus infection in women who have sex with women. J Infect Dis (1998) 1.77
Elution of "blocking factors" from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Int J Cancer (1972) 1.76
The x-ray structure of an anti-tumour antibody in complex with antigen. Nat Struct Biol (1995) 1.76
Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res (1986) 1.75
Evidence of prevalent genital-type human papillomavirus infections in adults and children. J Infect Dis (1990) 1.74
In vitro studies of immune reactions against autochthonous and syngeneic mouse tumors induced by methylcholanthrene and plastic discs. Int J Cancer (1968) 1.73
Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst (1997) 1.72
Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells. Oncogene (1996) 1.71
Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A (1981) 1.70
Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol (1994) 1.70
Nucleotide sequence of the herpes simplex virus type 2 thymidine kinase gene. J Virol (1983) 1.70
Immunological tolerance: "forbidden clones" allowed in tetraparental mice. Proc Natl Acad Sci U S A (1971) 1.67
Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol (2001) 1.66
Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A (1987) 1.61
Characterization of the gene encoding herpes simplex virus type 2 glycoprotein C and comparison with the type 1 counterpart. J Virol (1985) 1.60
Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res (1995) 1.59
E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J Virol (2001) 1.58
Costimulation of T cells for tumor immunity. Immunol Today (1993) 1.57
Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res (1990) 1.57
Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol (1996) 1.57
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Cellular immunity and its serum-mediated inhibition in Shope-virus-induced rabbit papillomas. Int J Cancer (1969) 1.56
Sequence and structural requirements of a herpes simplex viral DNA replication origin. Mol Cell Biol (1988) 1.55
Transformation of rodent cells by a cloned DNA fragment of herpes simplex virus type 2. J Virol (1981) 1.54
Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins. J Virol (1988) 1.51
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science (1993) 1.47
The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol (1989) 1.47
Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A (1991) 1.47